The landmark FLOW study shows the benefits extend to kidney, cardiovascular, and mortality outcomes in high-risk patients with type 2 diabetes and CKD.Medscape Medical News (Source: Medscape Medical News Headlines)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.